Le Lézard

FDA Approves Omeros' YARTEMLEA® ? First and Only Therapy Indicated for TA-TMA

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

FDA Approves Omeros' First-In-Class Drug For Rare Transplant Complication

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

FDA Approves Omeros' YARTEMLEA(R) -- First and Only Therapy Indicated for TA-TMA

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Medical Dialogues

FDA Approves First Treatment for HSCT-Associated Thrombotic Microangiopathy

The U.S. FDA has approved narsoplimab (Yartemlea) as the first indicated therapy for hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults and children aged ...

Best BPC-157 Oral Supplements: ProHealth's Triple-Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026

Third-Party Lab Testing, Bioavailability Questions, and Regulatory Status ExaminedCARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) ...
Gut

Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B

Background PD-1 blockade has emerged as a promising approach for functional cure of chronic hepatitis B (CHB). Objective This study aimed to evaluate the safety profile of anti-PD-1 antibody (αPD-1), ...